Profile - To The Moon

森林之心

Posts · 4Posts · 4
Following · 0Following · 0
Followers · 0Followers · 0

- 森林之心森林之心
  ·2021-06-07
  ??????
  Keji Pharmaceutical-B will launch its IPO today, and the first-hand admission fee is about HK $16,565.26
  科济药业-B(02171)6月7日-6月10日招股。公司发行9474.7万股。其中90%为国际发售，10%为公开发售，另有不超过15%超额配股权。每股发行价29.6-32.8港元(单位下同)；每手50
  Keji Pharmaceutical-B will launch its IPO today, and the first-hand admission fee is about HK $16,565.26
  606 Comment
  Like
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3583532696513131","uuid":"3583532696513131","gmtCreate":1620566641622,"gmtModify":1620566641622,"name":"森林之心","pinyin":"slzxsenlinzhixin","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":50,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":114956592,"gmtCreate":1623044767316,"gmtModify":1704194938776,"author":{"id":"3583532696513131","authorId":"3583532696513131","name":"森林之心","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583532696513131","authorIdStr":"3583532696513131"},"themes":[],"htmlText":"??????","listText":"??????","text":"??????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114956592","repostId":"1111166557","repostType":4,"repost":{"id":"1111166557","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623030069,"share":"https://ttm.financial/m/news/1111166557?lang=en_US&edition=fundamental","pubTime":"2021-06-07 09:41","market":"hk","language":"zh","title":"Keji Pharmaceutical-B will launch its IPO today, and the first-hand admission fee is about HK $16,565.26","url":"https://stock-news.laohu8.com/highlight/detail?id=1111166557","media":"老虎资讯综合","summary":"科济药业-B(02171)6月7日-6月10日招股。公司发行9474.7万股。其中90%为国际发售，10%为公开发售，另有不超过15%超额配股权。每股发行价29.6-32.8港元(单位下同)；每手50","content":"<p>Keji Pharmaceutical-B (02171) IPO from June 7th to June 10th. The company issued 94.747 million shares. Among them, 90% is an international offering, 10% is a public offering, and there is an over-allotment option of no more than 15%. The issue price per share is HK $29.6-32.8 (the same unit below); 500 shares per lot, expected to be listed on June 18.</p><p><img src=\"https://static.tigerbbs.com/f9ffdd89cc2ae2a0349c2756dd3e3c43\" tg-width=\"600\" tg-height=\"566\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot of 200 shares, admission fee of HK $16,565.26.</p><p>The threshold for Group B is 200,000 shares, and the funds required for subscription are approximately HK $6,626,105.12.</p><p><img src=\"https://static.tigerbbs.com/b0daf28231122d9f7e2ebbe6e14c9b64\" tg-width=\"685\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p><p>Company is a biopharmaceutical company. The company currently has no products approved for commercial sales and has not yet generated any revenue from product sales. From 2019 to 2020, the company's research and development expenses were RMB 210 million and RMB 280 million respectively.</p><p>The company has introduced a total of 9 cornerstone investors, and the cornerstone subscription accounts for about 60% of the global offering. Calculated at the lower limit price, the cornerstone accounts for 63.64%. Among them, LAV entity, a close contact of the company, subscribed for US $50 million, Xinhua Capital, a subsidiary of New China Life Insurance, subscribed for US $45 million, Ruiyuan, a subsidiary of Orient Securities, subscribed for US $30 million, WT Fund, GF Fund, Dymon Asia Capital, Ivy, and Southern Fund, a subsidiary of Huatai Securities, etc. are the cornerstones.</p><p><img src=\"https://static.tigerbbs.com/4cc47fa62c5af542ad22afb4472f5af6\" tg-width=\"780\" tg-height=\"538\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keji Pharmaceutical-B will launch its IPO today, and the first-hand admission fee is about HK $16,565.26</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeji Pharmaceutical-B will launch its IPO today, and the first-hand admission fee is about HK $16,565.26\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-07 09:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Keji Pharmaceutical-B (02171) IPO from June 7th to June 10th. The company issued 94.747 million shares. Among them, 90% is an international offering, 10% is a public offering, and there is an over-allotment option of no more than 15%. The issue price per share is HK $29.6-32.8 (the same unit below); 500 shares per lot, expected to be listed on June 18.</p><p><img src=\"https://static.tigerbbs.com/f9ffdd89cc2ae2a0349c2756dd3e3c43\" tg-width=\"600\" tg-height=\"566\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot of 200 shares, admission fee of HK $16,565.26.</p><p>The threshold for Group B is 200,000 shares, and the funds required for subscription are approximately HK $6,626,105.12.</p><p><img src=\"https://static.tigerbbs.com/b0daf28231122d9f7e2ebbe6e14c9b64\" tg-width=\"685\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p><p>Company is a biopharmaceutical company. The company currently has no products approved for commercial sales and has not yet generated any revenue from product sales. From 2019 to 2020, the company's research and development expenses were RMB 210 million and RMB 280 million respectively.</p><p>The company has introduced a total of 9 cornerstone investors, and the cornerstone subscription accounts for about 60% of the global offering. Calculated at the lower limit price, the cornerstone accounts for 63.64%. Among them, LAV entity, a close contact of the company, subscribed for US $50 million, Xinhua Capital, a subsidiary of New China Life Insurance, subscribed for US $45 million, Ruiyuan, a subsidiary of Orient Securities, subscribed for US $30 million, WT Fund, GF Fund, Dymon Asia Capital, Ivy, and Southern Fund, a subsidiary of Huatai Securities, etc. are the cornerstones.</p><p><img src=\"https://static.tigerbbs.com/4cc47fa62c5af542ad22afb4472f5af6\" tg-width=\"780\" tg-height=\"538\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1843fd3dbead1ca6cb2ae7c39aeb579a","relate_stocks":{"02171":"科济药业-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111166557","content_text":"科济药业-B(02171)6月7日-6月10日招股。公司发行9474.7万股。其中90%为国际发售，10%为公开发售，另有不超过15%超额配股权。每股发行价29.6-32.8港元(单位下同)；每手500股，预期6月18日上市。申购阶梯：每手200股，入场费16,565.26港元。乙组门槛为20万股，申购所需资金约6,626,105.12港元。公司是生物制药公司。公司目前并无获批准商业化销售的产品及尚未从产品销售产生任何收益。2019年-2020年公司研发开支分别为人民币2.1亿元及2.8亿元。公司共引入9名基石投资者，基石认购占全球发售比重的约60%，以下限价格计算，基石占比63.64%。其中，公司紧密联系人LAV实体认购5000万美元，新华保险旗下新华资本认购4500万美元，东方证券旗下睿远认购3000万美元，WT基金、广发基金、Dymon亚洲资本、常春藤、华泰证券旗下的南方基金等为基石。","news_type":1,"symbols_score_info":{"02171":0.9}},"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}